Matthew on for Alex Stramahan's questions to Day One Biopharmaceuticals Inc (DAWN) leadership • Q2 2025
Question
Representing Bank of America, Matthew asked if the ratio of new to repeat Ogenda prescriptions remained constant from Q1 to Q2 and how patient dropout trends were being influenced by recent ASCO data on managing skin adverse events.
Answer
CCO Lauren Merendino stated that dropout rates have been consistent and that the company is focused on driving new patient starts. CEO Jeremy Bender added that while it's too soon to see a dramatic impact in the data, the ASCO rash management information is an important tool for preventing premature discontinuations, and overall persistence is trending positively as physician experience grows.